Cardiopulmonary Inflammation and Multi-System Imaging During the Clinical Course of COVID-19 Infection in Asymptomatic and Symptomatic Persons
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04401449 |
Recruitment Status :
Recruiting
First Posted : May 26, 2020
Last Update Posted : January 13, 2021
|
Tracking Information | |||||
---|---|---|---|---|---|
First Submitted Date | May 22, 2020 | ||||
First Posted Date | May 26, 2020 | ||||
Last Update Posted Date | January 13, 2021 | ||||
Actual Study Start Date | January 8, 2020 | ||||
Estimated Primary Completion Date | May 1, 2024 (Final data collection date for primary outcome measure) | ||||
Current Primary Outcome Measures |
Inflammatory responses of cells in lung and circulation [ Time Frame: From onset of illness in hospital through acute phase ( days 1 28 more or less 7), at the time of resolution of infection ( day 28 more or less 7 to 6 weeks, andduring convalescence (6 months to 1 year after the infection) ] Link inflammatory responses present in blood, urine and bronchoalveolar lavage with imaging of COVID-19 target organs (lungs, heart, brain and kidneys) during the earliest stages of infection and at subsequent time points as the infection and host responses evolve, through recovery.
|
||||
Original Primary Outcome Measures | Same as current | ||||
Change History | |||||
Current Secondary Outcome Measures | Not Provided | ||||
Original Secondary Outcome Measures | Not Provided | ||||
Current Other Pre-specified Outcome Measures | Not Provided | ||||
Original Other Pre-specified Outcome Measures | Not Provided | ||||
Descriptive Information | |||||
Brief Title | Cardiopulmonary Inflammation and Multi-System Imaging During the Clinical Course of COVID-19 Infection in Asymptomatic and Symptomatic Persons | ||||
Official Title | Cardiopulmonary Inflammation and Multi-System Imaging During the Clinical Course of COVID-19 Infection in Asymptomatic and Symptomatic Persons (COVID ARC 19) | ||||
Brief Summary | Background: COVID-19 virus infection differs among people. Some people have no or mild symptoms. For others, COVID-19 is life threatening and causes damage to the body s organs. Researchers want to better understand the virus to learn how to kill it. Objective: To understand how the COVID-19 virus causes wide differences in how sick one can become from the infection. Eligibility: People ages 18-80 with COVID-19 infection Design: Participants will be screened with a review of their medical records. Participants who enter the study at the beginning of their COVID-19 infection will stay in the hospital until they are healthy enough to go home. Those who enter after they have recovered may need to stay in the hospital 1-2 nights to perform the study tests. Participants will have MRI and CT scans of the brain, heart, and lungs. They will lie in a machine that takes pictures of the body. For the MRI, soft padding or a coil will be placed around their head and chest. They may receive a dye injected into a vein. Participants will have an ultrasound of the kidneys and heart. Participants will provide blood and urine samples. They will provide nasal swabs. Participants will have a bronchoscopy. A thin tube will be placed through the nose or mouth into the airway. Saltwater will be squirted into the lungs and removed by suction. Participants may provide a spinal fluid sample. A needle injected into the spinal canal will obtain fluid. Participants will have lung and heart function tests. At various points after recovery, participants will repeat many of these tests. |
||||
Detailed Description | There is little sequential, methodically collected data on patients with COVID-19 that can be correlated with the severity of disease or the long-term sequelae. Such information is necessary to understand how to most logically intervene with directly acting antiviral agents and immunologic response modifiers. The variability of the clinical course of patients who may be asymptomatic throughout their clinical course to those patients who develop progressive multisystem organ failure represents a challenge to understand the host and viral factors that result in these dramatically different outcomes. This protocol will enroll patients to the Clinical Center in a longitudinal study using granular clinical, laboratory, and imaging data including extensive pulmonary and cardiac functional assessments, neurologic evaluation, comprehensive immunologic evaluations, and innovative imaging. In patients with COVID-19 infection, linking sequential analysis of blood, urine and bronchoalveolar lavage with simultaneous cardiopulmonary imaging can provide novel insights into mechanisms associated with the initiation, progression and resolution of lung, cardiac and systemic inflammation. These mechanisms are presumed to be essential in the pathogenesis and survival from this infection. This information will help guide diagnostic and therapeutic innovation and assess long-term consequences of this infection. |
||||
Study Type | Observational | ||||
Study Design | Observational Model: Cohort Time Perspective: Prospective |
||||
Target Follow-Up Duration | Not Provided | ||||
Biospecimen | Not Provided | ||||
Sampling Method | Probability Sample | ||||
Study Population | Subjects 18-80 years old, male or female will be enrolled within 14 - 28 days of documented COVID-19 infection for acute care OR during recovery and convalescent phase of the acute illness (day 28 and beyond) if care has been received at a facility outside of NIH. Subject will be from the MDV medtropolitan area. | ||||
Condition |
|
||||
Intervention | Not Provided | ||||
Study Groups/Cohorts |
|
||||
Publications * |
|
||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||
Recruitment Information | |||||
Recruitment Status | Recruiting | ||||
Estimated Enrollment |
180 | ||||
Original Estimated Enrollment |
92 | ||||
Estimated Study Completion Date | May 1, 2024 | ||||
Estimated Primary Completion Date | May 1, 2024 (Final data collection date for primary outcome measure) | ||||
Eligibility Criteria |
In order to be eligible to participate in this study, an individual must meet all of the following criteria: Subjects within 1-28 days of documented COVID-19 infection for acute care:
provided at the CC would present a disadvantage to them to have their acute care provided for in the CC.
Subjects during recovery phase of the acute illness (day 28 and beyond) if care has been received at a facility outside of NIH:
EXCLUSION CRITERIA: An individual who meets any of the following criteria will be excluded from participation in this study:
|
||||
Sex/Gender |
|
||||
Ages | 18 Years to 80 Years (Adult, Older Adult) | ||||
Accepts Healthy Volunteers | No | ||||
Contacts |
|
||||
Listed Location Countries | United States | ||||
Removed Location Countries | |||||
Administrative Information | |||||
NCT Number | NCT04401449 | ||||
Other Study ID Numbers | 200113 20-CC-0113 |
||||
Has Data Monitoring Committee | Not Provided | ||||
U.S. FDA-regulated Product |
|
||||
IPD Sharing Statement | Not Provided | ||||
Responsible Party | National Institutes of Health Clinical Center (CC) | ||||
Study Sponsor | National Institutes of Health Clinical Center (CC) | ||||
Collaborators | Not Provided | ||||
Investigators |
|
||||
PRS Account | National Institutes of Health Clinical Center (CC) | ||||
Verification Date | December 7, 2020 |